Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
12/2010
12/01/2010CN101322725B Preparation of plant parhormone for treating hypertrophy of the prostate
12/01/2010CN101167924B Method for producing traditional Chinese medicine preparation of six ingredients with rehmannia
12/01/2010CN101095698B Use of Clostridium Butyricum for preventing and treating foetid faeces toxin syndrome and disease
12/01/2010CN101032608B Chinese traditional medicine to be taken orally for curing urinary tract infection
11/2010
11/30/2010US7842698 Autoimmune diseases; antiinflamamtory agents, cardiovascular disorders; neurodegenerative diseases, kidney diseases, anticancer agents; platelet aggregation
11/30/2010CA2482858C Tricyclic thrombin receptor antagonists
11/30/2010CA2456817C Alkyne-aryl-naphthyridin-4 (1h)-one derivatives as type iv phosphodiesterase inhibitor
11/30/2010CA2449352C Nsaid formulation comprising a granular composition and an extra-granular composition
11/30/2010CA2440218C Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use as adenosine receptor-selective ligands
11/30/2010CA2295876C Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
11/25/2010WO2010135541A2 Variants of c-type natriuretic peptide
11/25/2010WO2010135536A2 Methods of modulating uric acid levels
11/25/2010WO2010133740A1 Mps cell genetically modified to overexpress ngal and the use thereof as a drug
11/25/2010WO2010133314A1 Medication for oral administration, comprising at least one estrogen and/or at least one gestagen and at least one probiotic bacterial strain
11/25/2010WO2010132959A1 Use of dynamin ring stabilizers
11/25/2010US20100298628 Stress urinary incontinence treatment
11/25/2010US20100298413 Use of oligotide for the treatment of renal diseases
11/25/2010US20100298402 Stilbene derivatives as pstat3/il-6 inhibitors
11/25/2010US20100298367 Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders
11/25/2010US20100298337 Organic Compounds
11/25/2010US20100298326 Carboxamide compounds and their use as calpain inhibitors
11/25/2010US20100298310 Thiazole Derivatives as Kinase Inhibitors
11/25/2010US20100298307 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use
11/25/2010US20100298289 Heterobicyclic compounds as histamine h4-receptor antagonists
11/25/2010US20100298285 Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
11/25/2010US20100298274 Fat containing composition
11/25/2010US20100298248 Biologically active macrolides, compositions, and uses thereof
11/25/2010US20100298225 Peptide gap junction modulators
11/25/2010US20100297241 Amorphous Fesoterodine Fumarate
11/25/2010US20100297233 Oscillating cell culture bioreactor
11/25/2010US20100297230 Compositions and methods for prostate and menstrual/menopausal related health
11/25/2010US20100297225 Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
11/25/2010US20100297209 Solvent/polymer solutions as suspension vehicles
11/25/2010US20100297139 Methods and compositions for the treatment of proteinuric diseases
11/25/2010US20100297084 method for transducing cells with primary cilia
11/25/2010US20100297078 Method for producing a hydroxyalkyl starch derivative with two linkers
11/25/2010US20100297021 Variants of C-Type Natriuretic Peptide
11/25/2010CA2762640A1 Medication for oral administration, comprising at least one estrogen and/or at least one gestagen and at least one probiotic bacterial strain
11/25/2010CA2762600A1 Use of dynamin ring stabilizers
11/25/2010CA2760940A1 Methods of modulating uric acid levels
11/24/2010EP2253620A1 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
11/24/2010EP2253327A1 Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound
11/24/2010EP1546375B1 Nucleic acids, polypeptides, and methods for modulating apoptosis
11/24/2010EP1539739B1 Piperidinyl compounds that selectively bind integrins
11/24/2010CN1942181B Tablet containing branched chain amino acid and process for producing the same
11/24/2010CN101896490A Trisubstituted piperidines as renin inhibitors
11/24/2010CN101891785A Extraction method of hyperin and application thereof in medicament preparation
11/24/2010CN101890166A Combination of organic compounds
11/24/2010CN101890165A Composition for lowering blood pressure and application thereof
11/24/2010CN101890163A Use of anti-tnfalpha antibodies and another drug
11/24/2010CN101890126A Decoction for treating urinary tract infection
11/24/2010CN101890066A Method for constructing Bidens parviflor willd medicinal material capillary electrophoresis fingerprint and application thereof
11/24/2010CN101890058A Health-care bio-chip based on nano-taxus and preparation method thereof
11/24/2010CN101890057A Chinese brake herb preparation for treating gastrointestinal tract and urinary tract infections and cardiovascular and cerebrovascular diseases and preparation method thereof
11/24/2010CN101890050A Human umbilical cordmesenchymal stem cell-derived exosome and application thereof
11/24/2010CN101890046A Composition with heart rate reducing properties
11/24/2010CN101890041A Peritoneal dialysis solution and preparation method thereof
11/24/2010CN101890038A Nuezhenoside-rhoifolin-hyperin composite and application in medicinal preparation thereof
11/24/2010CN101890037A Nuezhenoside and hyperin composition and application thereof for preparing medicine
11/24/2010CN101890011A Pharmaceutical composition containing amlodipine and stilbestrol
11/24/2010CN101889996A Rectal administration composition containing tamsulosin
11/24/2010CN101889953A Device and method for manufacturing drug smoke liquid and drug smoke
11/24/2010CN101889946A Smokeless black bean moxibustion instrument
11/24/2010CN101889736A Chinese medicinal health-care sock and production method thereof
11/24/2010CN101185698B Effective substance extracted from bastard speedwell for treating prostatitis and prostatic hyperplasia
11/24/2010CN101181353B Traditional Chinese medicine preparation for curing prostate gland disease and preparation method thereof
11/24/2010CN101167720B Application of iridoids compound in preparing medicine for treating benign prostate hyperplasia
11/23/2010US7838565 Suppresses reduction in peripheral nerve conduction rate and alleviates hypofunction of bladder so that it is useful as a preventive and/or therapeutic agent for, particularly, diabetic neuropathy
11/23/2010US7838289 Assay utilizing multipotent adult stem cells
11/23/2010US7838266 A purified pro-cytolytic peptide; used to treat localized and metastatic prostate cancer; administered intratumorally and/or intraprostatically
11/23/2010CA2459380C Reverse hydroxamic acid derivatives
11/23/2010CA2438870C Novel inhibitors of formation of advanced glycation endproducts (ages)
11/23/2010CA2373302C Conditioned cell culture medium compositions and methods of use
11/23/2010CA2315271C Platelet derived growth factor (pdgf) nucleic acid ligand complexes
11/18/2010WO2010132764A2 Live-attenuated compositions for bacterial infections
11/18/2010WO2010131738A1 Azetidine compound and medicinal use thereof
11/18/2010WO2010131712A1 Therapeutic pharmaceutical agent for diseases associated with decrease in function of gne protein, food composition, and food additive
11/18/2010WO2010131695A1 Modified double-stranded rna
11/18/2010WO2010130799A2 Method for impregnation with supercritical co2
11/18/2010WO2010130073A1 Itgb4bp and derivative thereof used in treatment and/or prevention of hyperplastic scar and fibrosis
11/18/2010US20100292314 Anti-angiogenic compositions and methods of use
11/18/2010US20100292235 Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
11/18/2010US20100292225 Aryl pyridine as aldosterone synthase inhibitors
11/18/2010US20100292201 Novel steroidal esters of 17-oximino-5-androsten-3beta-ol
11/18/2010US20100292182 Cystitis treatment with high dose chondroitin sulfate
11/18/2010US20100291218 Immunomodulatory compositions, formulations, and methods for use thereof
11/18/2010US20100291186 Transdermal Administration of Tamsulosin
11/18/2010US20100291173 Method of improving renal function
11/18/2010US20100291170 Novel therapies for chronic renal failure
11/18/2010US20100291151 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
11/18/2010US20100291099 Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
11/18/2010US20100291098 Diabetic nephropathy therapies
11/18/2010US20100291060 Subcutaneous administration of alpha-galactosidase a
11/18/2010DE102009021752A1 Verwendung monomerer iodhaltiger Kontrastmittel in hohen Dosierungen für Röntgendiagnostik, insbesondere für die intraventionelle Using monomeric iodinated contrast media in high dosages of Radiology, especially for the intraventionelle
11/18/2010CA2761853A1 Benzoxazolone derivatives as aldosterone synthase inhibitors
11/17/2010EP2251328A1 Crystalline 1-(3-fluorophenyl)-5-methyl-2-(1h)pyridone, the preparation methods, compositions and applications thereof
11/17/2010EP2251012A1 Tablet having improved elution properties
11/17/2010EP2249820A1 Trpa1 antagonists
11/17/2010EP1280486B1 Minimizing adverse experience associated with oxybutynin therapy
11/17/2010CN1839928B Chinese traditional medicine for treating chronic nephritis and its preparation process
1 ... 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 ... 562